Proteomics strategies for urothelial bladder cancer diagnosis, prognosis and treatment: Trends for tumor biomarker sources
Analytical Biochemistry · 2023
DOI: 10.1016/j.ab.2023.115074 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Analytical Biochemistry, 2023. Verfasst von Samira Tabaei und 3 weiteren Autor:innen. Beteiligte Einrichtung: Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; Department of Immunology, School of Me…. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 95 Literaturangaben. Gefördert von: University of British Columbia.
Abstract (Originalsprache)
Urothelial bladder cancer (UBC) is a heterogeneous multifactorial malignancy with a high recurrence rate. Current procedures for UBC diagnosis suffering from the lack of clinical sensitivity and specificity screening tests. Therefore, biomarkers have promising values to predict pathological conditions and can be considered as effective targets for early diagnosis, prognosis and antitumor immunotherapy. Recently, researchers have been interested for tumor proteins as biomarkers for different diseases. At present, proteomics methods have rapidly progressive that has potential identified biomarkers of UBC. Specifically, there has been several studies on the potential application of proteomics for the identification, quantification, and profiling of proteins for UBC in different sources. Based on these studies, using the panel of biomarkers as proteomic patterns may achieve higher sensitivity and specificity than single proteins in the diagnosis of UBC. In the present review, we evaluate recent literature related to the UBC proteome focusing especially on new proteomics techniques. Moreover, we classify UBC tumor biomarkers as diagnostic, prognostic, and therapeutic targets based on their sources (urine, serum/plasm, cell line, and tumor tissue) and we also discuss the advantages and limitations of each source. In this manner, this review article provides a critical assessment presentation of the advances in proteomics for all aspects of UBC diagnosis, prognosis, and treatment based on sources.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
- Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
- School of Biomedical Engineering and Health Sciences, Hebei University of Technology, Tianjin, China.
- Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Electroni…
Förderung
- University of British Columbia
Zitieren
APA
Tabaei, S., Haghshenas, M. R., Webster, T. J., & Ghaderi, A. (2023). Proteomics strategies for urothelial bladder cancer diagnosis, prognosis and treatment: Trends for tumor biomarker sources. Analytical Biochemistry. https://doi.org/10.1016/j.ab.2023.115074
Vancouver
Tabaei S, Haghshenas MR, Webster TJ, Ghaderi A. Proteomics strategies for urothelial bladder cancer diagnosis, prognosis and treatment: Trends for tumor biomarker sources. Analytical Biochemistry. 2023. doi:10.1016/j.ab.2023.115074
BibTeX
@article{Tabaei2023,
author = {Tabaei, Samira and Haghshenas, Mohammad Reza and Webster, Thomas J and Ghaderi, Abbas},
title = {Proteomics strategies for urothelial bladder cancer diagnosis, prognosis and treatment: Trends for tumor biomarker sources},
journal = {Analytical Biochemistry},
year = {2023},
doi = {10.1016/j.ab.2023.115074}
}
EUVIMED